Enhancing survival outcomes in unresectable hepatocellular carcinoma: a prospective cohort study on the effects of Huaier granules with targeted therapy plus immunotherapy.

Front Pharmacol · 2025 · PMC11983566 · PMID 40213688

Europe PMC DOI

hedged sentence

0.1488

closest p · 3.0× alpha

0.1488

boldest claim

The sentences

did not reach statistical significanceP = 0.1488not close (p > 0.1)

For patients treated with sintilimab plus bevacizumab, the mPFS was 6.8 months, compared to 5 months in patients who did not receive this combination, although this difference did not reach statistical significance (P = 0.1488).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.